Mitochondrial metabolism in early neural fate and its relevance for neuronal disease modeling

Lorenz, C., Prigione, A.

This is the final version of the accepted manuscript. The original article has been published in final edited form in:

Current Opinion in Cell Biology
2017 DEC ; 49: 71-76
2017 DEC 22 (first published online: final publication)
doi: 10.1016/j.ceb.2017.12.004

Publisher: Elsevier

Mitochondrial metabolism in early neural fate and its relevance for neuronal disease modeling

Authors and affiliations:

Carmen Lorenz[1,2], Alessandro Prigione[1§]

[1]Max Delbrueck Center for Molecular Medicine (MDC), 13125 Berlin, Germany

[2]Berlin Institute of Health (BIH), 10178 Berlin, Germany

[§]**Contact information**:

Alessandro Prigione, M.D. Ph.D. Robert-Roessle-Str. 10, 13125 Berlin, Germany. Phone: 0049-30-9406-2871, Fax: 0049-30-9406-3696, Email: alessandro.prigione@mdc-berlin.de.

Keywords: metabolism; neural stem cells; neurogenesis; mitochondria; neurodegeneration; mitochondrial disease

Abstract

Modulation of energy metabolism is emerging as a key aspect associated with cell fate transition. The establishment of a correct metabolic program is particularly relevant for neural cells given their high bioenergetic requirements. Accordingly, diseases of the nervous system commonly involve mitochondrial impairment. Recent studies in animals and in neural derivatives of human pluripotent stem cells (PSCs) highlighted the importance of mitochondrial metabolism for neural fate decisions in health and disease. The mitochondria-based metabolic program of early neurogenesis suggests that PSC-derived neural stem cells (NSCs) may be used for modeling neurological disorders. Understanding how metabolic programming is orchestrated during neural commitment may provide important information for the development of therapies against conditions affecting neural functions, including aging and mitochondrial disorders.

Within the nervous system, stem cells need to generate both neurons and glia [1–3]. Their derivation -collectively defined here as neurogenesis - requires the careful orchestration of cell type-specific epigenetic signatures. These signatures may be influenced by the metabolic state of the cells, given that metabolites can act as epigenetic regulators [4]. At the same time, the transcriptional reorganization associated with neural specification generates distinct metabolic programs that may also be cell type-specific and may in turn contribute to the correct establishment of the needed cellular identity.

Here, we discuss recent literature addressing how the metabolic programs of neurons and glia are constructed. The works have been conducted both in animals and in neural derivatives of human pluripotent stem cells (PSCs). It is important to point out that the generation of neural cells *in vitro* can be influenced by the culture conditions, including signaling molecules and oxygen levels [5]. Therefore, the metabolism of *in vitro* derived human neural cells may not necessarily mirror that of the actual neural cells residing in the human brain. Nonetheless, the use of human PSC neural derivatives is allowing for the first time to investigate the metabolic regulation of human brain cells.

Some of the recent findings that we will discuss here, generated from *in vivo* and *in vitro* experiments, have challenged the conventional idea associated with the metabolic remodeling of neurogenesis. The picture emerging is that metabolism is more plastic than previously expected and that it can be fine-tuned at different levels during neural commitment. We also comment on clinically relevant opportunities that are starting to be translated from these basic studies. We believe that this renewed interest in the metabolic contribution to neural specification may bring important insights for the study of diseases affecting the nervous system, including neurodegeneration and mitochondrial disorders.

Glycolytic metabolism and neurogenesis

The metabolic programs of neurons and glia are considered to be very divergent. Neurons are dependent on mitochondrial-based oxidative phosphorylation (OXPHOS) while glia rely on glycolysis [6,7]. Both cell types are generated from multipotent neural stem cells (NSCs), which appear to share some of the features of glial cells, including the reliance on glycolytic metabolism [2,8]. Given that the modulation of metabolism may be instrumental during neural commitment [9], it becomes critical to investigate how the cell type-specific metabolic programs are regulated.

The glycolytic nature of NSCs is usually explained by the fact that glycolysis is the preferred metabolic route of stemness [10]. Accordingly, PSC-derived neural progenitor cells (NPCs) have been found to depend on glycolytic metabolism [11]. Moreover, metabolic profiling of cells exiting pluripotency *in vitro* indicates that the metabolic switch towards OXPHOS does not occur uniformly for all germ layers, as ectodermal lineage and NPC induction still require the maintenance of a high glycolytic flux [12].

The picture becomes more complicated when we consider the proliferative rate of stem cells. In the case of PSCs, for example, the glycolytic metabolism is suggested to be a consequence of their elevated level of proliferation [13,14]. Highly proliferative cells like cancer cells prefer indeed glycolysis, since it provides the precursor molecules for biomass generation via the pentose phosphate pathway (PPP) that emerges from the upstream branches of glycolysis [15]. In the case of hematopoietic stem cells (HCS), however, glycolysis is considered to be chosen over OXPHOS due to the fact that HSCs do not actively proliferate and therefore do not have high bioenergetic needs [16,17]. These findings raise the question of why stem cells would prefer glycolysis regardless of their rate of proliferation. The relationship between proliferation and stem cell metabolism may be particularly important in the context of the nervous system. NSCs *in vivo* can in fact rapidly divide during development but become quiescent in adult age [18].

One possibility is that the stem cell reliance on glycolysis is linked to the regulation of redox metabolism. The use of glycolysis may reduce the intracellular levels of reactive oxygen species (ROS) generated as OXPHOS by-products and at the same time it may enhance the production of the antioxidant glutathione through the PPP-mediated generation of the NADPH [19]. ROS can also function as second messengers. The regulation of redox homeostasis may play a crucial role in the self-renewal of NSCs [20]. The physiological effect of ROS may contribute to the induction of neurogenesis *in vivo* [21]. Intermittent generation of ROS in proliferative NPCs in the developing cortex *in vivo* negatively influences their rate of proliferation [22], suggesting that low ROS levels are indeed beneficial for NPCs. Recent *in vivo* findings demonstrated that mouse embryonic NSCs exhibit reduced amount of ROS, while committed NPCs increase ROS production to promote differentiation [23]. NPC differentiation *in vivo* may be induced following a transcriptional program activated by the nuclear factor erythroid 2-related factor 2 (NRF2) [23]. NRF2 is indeed known to stimulate the expression of genes involved in redox signaling, thereby supporting neuronal differentiation by protecting against toxic insults [24].

The induction of glycolysis in NSCs might also be influenced by the level of oxygen and by the activation of hypoxia inducible factors (HIFs) [25]. This was found to be the case in the context of PSCs [26,27]. The oxygen sensing response can in fact be controlled by cellular ROS rather than by OXPHOS metabolism per se [28]. Nevertheless, the glycolytic metabolic state of *ex vivo* mouse NSCs has been found to be not dependent on HIFs [29]. At the same time, HIFs may be important in the *in vitro* derivation of NPCs from human PSCs, as the level of oxygen has been suggested to modulate whether NPCs can differentiate more efficiently into neurons or glia [30]. Therefore, the importance of HIF-mediated response in neurogenesis requires further investigations.

Another possibility for explaining the reliance on glycolysis of NSCs and glia and the reliance on OXPHOS in the case of neurons may be that these metabolic programs may

contribute to the epigenetic regulation of the respective cell fate. The process of establishing a cell fate identity requires a complex integration between environmental cues and transcriptional states [13]. In this scenario, cellular metabolism may represent the mechanism through which a cell responds to both exogenous stimuli and gene expression programs [4]. Within the complex regulation of epigenetics during neural cell commitment [31], however, the importance of metabolism still remains largely unexplored.

Mitochondrial metabolism and dynamics during neurogenesis

An important aspect that has been recently challenged of the classical view of metabolism in neurogenesis relates to the time point in which the oxidative metabolic program is activated and to the respective morphology of mitochondria.

As mentioned above, the NSC state is believed to be linked with glycolytic metabolism coupled to non-fused mitochondrial morphology, which is considered typical for glycolytic stem cells [32]. In the neural lineage, OXPHOS metabolism is usually associated only with differentiated neurons [7,33], which exhibit a tubular mitochondrial network. This has been confirmed in several recent works investigating the mitochondrial state of neurons derived *in vitro* from human PSCs [11,34,35]. Proteomics analysis further underscored the increase of OXPHOS-related proteins in differentiating neurons both *in vitro* and *in vivo* [36,37].

In contrast to the assumptions about the mitochondrial state of NSCs, recent findings demonstrated that mouse embryonic NSCs exhibit elongated mitochondria *in vivo* while remaining glycolytic [23]. At the same time, proliferative NPCs *in vivo* displayed non-fused fragmented mitochondria [23]. Mouse adult NSCs *in vivo* have been found to possess mitochondria with a mixed globular and tubular shape that becomes consistently more elongated in proliferative intermediate progenitor cells (IPCs) [38]. Consequently, single cell transcriptomics identified the up-regulation of OXPHOS components and the down-regulation of glycolytic enzymes during the transition between NSCs and IPCs *in vivo* [38].

In agreement with a potential activation of the oxidative metabolic program in early neural fate commitment, NPCs derived *in vitro* from human PSCs have been found to display tubular mitochondria and a reduction of glycolytic metabolism when compared to PSCs [39]. The apparent disagreement of these latter findings with other published works on PSC-derived NPCs [11,12], may perhaps be explained by the type of signaling molecules used for the derivation of NPCs *in vitro*. Glycolytic NPCs were cultivated using basal FGF [11], which may be per se associated with enhanced glycolysis [40]. Conversely, oxidative NPCs were grown with LIF [39], which promotes mitochondrial metabolism [41]. Collectively, these data indicate that activation of the OXPHOS program during neurogenesis may occur earlier than expected [42] and that it may be influenced by signaling and environmental cues **(Figure 1)**.

This novel concept of how metabolic programs are orchestrated during neural commitment underscores the metabolic plasticity associated with the cell fate transitions. In this emerging picture, it will be relevant to dissect the state of mitochondrial metabolism and dynamics of glia cells. Astrocytes are considered to be dependent on glycolytic metabolism, as they can produce glycolysis-derived lactate that is then secreted and used to fuel neurons [6]. Oligodendrocytes also rely on glycolysis [43], further supporting the metabolic compartmentalization of the central nervous system. Nonetheless, the lactate produced by astrocytes and oligodendrocytes can also be obtained from pyruvate generated from malate coming from the mitochondrial tricarboxylic acid (TCA) cycle [44]. Hence, mitochondrial metabolism might also be potentially relevant for glial cells. Accordingly, glioblastoma cells forced to increase OXPHOS and mitochondrial biogenesis efficiently differentiate into astrocytes [45].

Understanding the relevance of mitochondria for glia cells might be important for facilitating the reprogramming of astrocytes into neurons [46], given that metabolism represents a critical roadblock in this process [47]. The investigation of astrocytic mitochondria may also provide essential clues to explain the phenomenon of mitochondrial

transfer between astrocytes and neurons that has been reported to occur *in vivo* in mice following ischemic insults [48].

Targeting mitochondria for improving neurogenesis in neurological diseases

Mitochondrial defects are a known pathogenetic mechanism involved in conditions causing neurological impairment, including aging-associated neurodegeneration [49]. At the same time, mitochondrial disorders due to OXPHOS mutations usually cause symptoms at the level of the nervous system [50]. The findings discussed above open new avenues in our understanding of these human diseases and in the development of therapies.

If OXPHOS metabolism is relevant not only for fully differentiated neurons but also for proliferative neural precursors, diseases impairing mitochondria could also affect neurogenesis and targeting mitochondrial function may represent a strategy for improving neural defects [51]. Accordingly, piracetam-mediated activation of mitochondrial respiration promoted neurogenesis *in vivo* in aged mice [38]. Furthermore, mitochondrial dysfunctions due to PINK1 deficiency caused defective neurogenesis in a mouse model of Parkinson's disease [52]. Enhanced mitochondrial function upon modulation of microRNA-210 led to improved NSC proliferation and differentiation *in vitro* following inflammatory insults [53].

The findings also suggest that iPSC-derived NPCs may represent a viable model for investigating neurological diseases. NPCs from patients affected by schizophrenia have been found to exhibit disease-associated phenotypes [54]. The use of NPCs may particularly be important for mitochondrial disorders that are caused by mutations in the mitochondrial DNA (mtDNA) and for which there is a lack of viable modeling systems [55]. iPSC-derived NPCs from patients affected by Leigh syndrome carrying a mtDNA mutation in the gene *MT-ATP6* have been used for the establishment of a drug discovery platform [39]. Leigh syndrome NPCs displayed a defect in calcium homeostasis that was observed in neurons but not in other peripheral cells [39]. The observed NPC defects might imply that Leigh syndrome also affects

neurogenesis. Interestingly, hypoxia stimulation was recently shown to significantly improve the life-span of a mouse model of Leigh syndrome [56]. The mechanisms underlying the beneficial effect of hypoxia in the Leigh syndrome mice remain unclear. However, given the above-mentioned importance of redox metabolism and HIFs signaling for NSCs and their glycolytic state, it is perhaps possible that hypoxic exposure may be beneficial to Leigh syndrome mice because it promotes NSC proliferation and neurogenesis.

In conclusion, the recent data addressing how the metabolic programs of neural cells are established *in vitro* and *in vivo* is challenging the traditional view of neurogenesis and is opening new ways to approach and cure disorders of the nervous system. A deeper understanding of the metabolic programming occurring upon neural fate commitment will shed new lights on how brain cells are generated and how we can develop strategies to restore their function during disease states.

Acknowledgements

The authors declare no competing financial or commercial interests. We acknowledge financial support from the German Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) (e:Bio Young Investigator grant #AZ.031A318), the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) (PR1527/1-1), and the Berlin Institute of Health (BIH).

References

1. Goncalves JT, Schafer ST, Gage FH: **Adult neurogenesis in the hippocampus: From stem cells to behavior**. *Cell* 2016, **167**:897–914.

2. Kriegstein A, Alvarez-buylla A: **The glial nature of embryonic and adult neural**

stem cells. *Annu Rev Neurosci* 2009, **32**:149–184.

3. Götz M, Sirko S, Beckers J, Irmler M: **Reactive astrocytes as neural stem or progenitor cells: In vivo lineage, In vitro potential, and Genome-wide expression analysis**. *Glia* 2015, **63**:1452–1468.
4. Gut P, Verdin E: **The nexus of chromatin regulation and intermediary metabolism**. *Nature* 2013, **502**:489–498.
5. Brennand KJ, Marchetto MC, Benvenisty N, Brüstle O, Ebert A, Izpisua Belmonte JC, Kaykas A, Lancaster MA, Livesey FJ, McConnell MJ, et al.: **Creating Patient-Specific Neural Cells for the in Vitro Study of Brain Disorders**. *Stem Cell Reports* 2015, **5**:933–945.
6. Magistretti PJ, Allaman I: **A cellular perspective on brain energy metabolism and functional imaging**. *Neuron* 2015, **86**:883–901.
7. Hall CN, Klein-Flugge MC, Howarth C, Attwell D: **Oxidative phosphorylation, not glycolysis, powers presynaptic and postsynaptic mechanisms underlying brain information processing**. *J Neurosci* 2012, **32**:8940–8951.
8. Candelario KM, Shuttleworth CW, Cunningham LA: **Neural stem/progenitor cells Display a low requirement for oxidative metabolism independent of hypoxia inducible factor-1 alpha expression**. *J Neurochem* 2013, **125**:420–429.
9. Knobloch M, Braun SMG, Zurkirchen L, von Schoultz C, Zamboni N, Araúzo-Bravo MJ, Kovacs WJ, Karalay O, Suter U, Machado RAC, et al.: **Metabolic control of adult neural stem cell activity by Fasn-dependent lipogenesis.** *Nature* 2013, **493**:226–30.
10. Folmes CDL, Terzic A: **Energy Metabolism in the Acquisition and Maintenance of Stemness**. *Semin Cell Dev Biol* 2016, **52**:68–75.
11. Zheng X, Boyer L, Jin M, Mertens J, Kim Y, Ma L, Ma L, Hamm M, Gage FH, Hunter T: **Metabolic reprogramming during neuronal differentiation from aerobic**

glycolysis to neuronal oxidative phosphorylation. *Elife* 2016, **5**:1–25.

***In this work, the authors used human iPSCs to investigate the conversion from glycolytic NPCs to oxidative neurons. They reported the down-regulation of MYC, HK2, and LHDA and the parallel induction of PGC-1α and ERRγ, which they found essential to maintain -rather than increase- the expression of OXPHOS genes.**

12. Cliff TS, Wu T, Boward BR, Yin A, Yin H, Glushka JN, Prestegaard JH, Dalton S: **MYC controls human pluripotent stem cell fate decisions through regulation of metabolic flux**. *Cell Stem Cell* 2017, **21**:1–15.

***This study demonstrated that a switch from glycolysis to OXPHOS is required for the induction of mesoderm and endoderm from human iPSCs but not for early ectoderm specification. The authors showed that high glycolytic flux and MYC activity are needed for the induction of NPCs and neural crest cells.**

13. Wu J, Ocampo A, Izpisua Belmonte JC: **Cellular metabolism and induced pluripotency**. *Cell* 2016, **166**:1371–1385.

14. Prigione A, Fauler B, Lurz R, Lehrach H, Adjaye J: **The senescence-related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent stem cells.** *Stem Cells* 2010, **28**:721–733.

15. Vander Heiden MG, Cantley LC, Thompson CB: **Understanding the Warburg effect: The metabolic requiremetns of cell proliferation**. *Science (80-)* 2009, **324**:1029–1033.

16. Beckervordersandforth R: **Mitochondrial metabolism-mediated regulation of adult neurogenesis**. *Brain Plast* 2017, doi:10.3233/BPL-170044.

17. Ito K, Suda T: **Metabolic requirements for the maintenance of self-renewing stem cells**. *Nat Rev Mol Cell Biol* 2014, **15**:243–256.

18. Furutachi S, Miya H, Watanabe T, Kawai H, Yamasaki N, Harada Y, Imayoshi I,

Nelson M, Nakayama KI, Hirabayashi Y, et al.: **Slowly dividing neural progenitors are an embryonic origin of adult neural stem cells**. *Nat Neurosci* 2015, **18**:657–665.

19. Stincone A, Prigione A, Cramer T, Wamelink MMC, Campbell K, Cheung E, Olin-Sandoval V, Gruening N-M, Krueger A, Tauqeer Alam M, et al.: **The return of metabolism: biochemistry and physiology of the pentose phosphate pathway.** *Biol Rev Camb Philos Soc* 2015, **90**:927–963.

20. Prozorovski T, Schneider R, Berndt C, Hartung H-P, Aktas O: **Redox-regulated fate of neural stem progenitor cells**. *Biochim Biophys Acta* 2015, **1850**:1543–1554.

21. Le Belle JE, Orozco NM, Paucar AA, Saxe JP, Mottahedeh J, Pyle AD, Wu H, Kornblum HI: **Proliferative neural stem cells have high endogenous ROS levels that regulate self-renewal and neurogenesis in a PI3K/Akt-dependant manner**. *Cell Stem Cell* 2011, **8**:59–71.

22. Hou Y, Ouyang X, Wan R, Cheng H, Mattson MP, Cheng A: **Mitochondrial superoxide production negatively regulates neural progenitor proliferation and cerebral cortical development.** *Stem Cells* 2012, **30**:2535–47.

23. Khacho M, Clark A, Svoboda DS, Azzi J, MacLaurin JG, Meghaizel C, Sesaki H, Lagace DC, Germain M, Harper ME, et al.: **Mitochondrial dynamics impacts stem cell identity and fate decisions by regulating a nuclear transcriptional program**. *Cell Stem Cell* 2016, **19**:232–247.

****This study demonstrates that mitochondrial dynamics regulates NSC identity. Contrary to previous knowledge, the authors showed that mouse embryonic NSCs exhibit elongated mitochondria, which impact stemness through a ROS-mediated process involving NRF2 signaling**

24. Kärkkäinen V, Pomeshchik Y, Savchenko E, Magga J, Kanninen KM, Koistinaho J: **Nrf2 regulates neurogenesis and protects neural progenitor cells against A b toxicity.** *Stem Cells* 2014, **32**:1904–1916.

25. Semenza GL: **Life with oxygen**. *Science (80-)* 2007, **318**:62–64.

26. Prigione A, Rohwer N, Hoffmann S, Mlody B, Bukowiecki R, Wanker EE, Ralser M, Cramer T, Adjaye J: **HIF1a modulates cell fate reprogramming through early glycolytic shift and upregulation of PDK1–3 and PKM2**. *Stem Cells* 2014, **32**:364–376.

27. Mathieu J, Zhou W, Xing Y, Sperber H, Ferreccio A, Agoston Z, Kuppusamy KT, Moon RT, Ruohola-Baker H: **Hypoxia inducible factors have distinct and stage-specific roles during reprogramming of human cells to pluripotency**. *Cell Stem Cell* 2014, **14**:592–605.

28. Brunelle JK, Bell EL, Quesada NM, Vercauteren K, Tiranti V, Zeviani M, Scarpulla RC, Chandel NS: **Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation**. *Cell Metab* 2005, **1**:409–414.

29. Candelario KM, Shuttleworth CW, Cunningham LA: **Neural stem/progenitor cells display a low requirement for oxidative metabolism independent of hypoxia inducible factor-1alpha expression.** *J Neurochem* 2013, **125**:420–429.

30. Xie Y, Zhang J, Lin Y, Gaeta X, Meng X, Wisidagama DRR, Cinkornpumin J, Koehler CM, Malone CS, Teitell MA, et al.: **Defining the role of oxygen tension in human neural progenitor fate**. *Stem Cell Reports* 2014, **3**:743–757.

31. Imamura T, Uesaka M, Nakashima K: **Epigenetic setting and reprogramming for neural cell fate determination and differentiation.** *Philos Trans R Soc Lond B Biol Sci* 2014, **369**:20130511.

32. Chen H, Chan DC: **Mitochondrial dynamics in regulating the unique phenotypes of cancer and stem cells**. *Cell Metab* 2017, **26**:39–48.

33. Rafalski V a, Brunet A: **Energy metabolism in adult neural stem cell fate.** *Prog Neurobiol* 2011, **93**:182–203.

34. O'Brien LC, Keeney PM, Bennett JP: **Differentiation of human neural stem cells**

into motor neurons stimulates mitochondrial biogenesis and decreases glycolytic flux. *Stem Cells Dev* 2015, **24**:1984–1994.

35. Fang D, Qing Y, Yan S, Chen D, Yan SSD: **Development and dynamic regulation of mitochondrial network in human midbrain dopaminergic neurons differentiated from iPSCs**. *Stem Cell Reports* 2016, **7**:678–692.

36. Fathi A, Hatami M, Vakilian H, Han C-L, Chen Y-J, Baharvand H, Salekdeh GH: **Quantitative proteomics analysis highlights the role of redox hemostasis and energy metabolism in human embryonic stem cell differentiation to neural cells**. *J Proteomics* 2014, **101**:1–16.

37. Frese CK, Mikhaylova M, Stucchi R, Gautier V, Liu Q, Mohammed S, Heck AJR, Altelaar AFM, Hoogenraad CC: **Quantitative map of proteome Dynamics during neuronal differentiation**. *Cell Rep* 2017, **18**:1527–1542.

38. Beckervordersandforth R, Ebert B, Schäffner I, Moss J, Fiebig C, Shin J, Moore DL, Ghosh L, Trinchero MF, Stockburger C, et al.: **Role of mitochondrial metabolism in the control of early lineage progression and aging phenotypes in adult hippocampal neurogenesis**. *Neuron* 2017, **93**:560–573.

****This work provides the first evidence that mitochondrial function influence adult neurogenesis in mice. The authors discovered that OXPHOS metabolism is essential for proliferative IPCs: its impairment was associated with aging-related decline in neurogenesis and its pharmacological enhancement with piracetam ameliorated age-associated neurogenetic defects.**

39. Lorenz C, Lesimple P, Bukowiecki R, Zink A, Inak G, Mlody B, Singh M, Semtner M, Mah N, Auré K, et al.: **Human iPSC-derived neural progenitors are an effective drug discovery model for neurological mtDNA disorders**. *Cell Stem Cell* 2017, **20**:659–674.

****In this work, the authors demonstrated that NPCs generated from human**

iPSCs can already exhibit elongated mitochondrial and a reliance on OXPHOS metabolism. The authors used these properties to develop a NPC-based drug discovery model of Leigh syndrome caused by a mtDNA mutation that allowed the identification of a potential novel therapy.

40. Zhou W, Choi M, Margineantu D, Margaretha L, Hesson J, Cavanaugh C, Blau CA, Horwitz MS, Hockenbery D, Ware C, et al.: **HIF1α induced switch from bivalent to exclusively glycolytic metabolism during ESC-to-EpiSC/hESC transition**. *EMBO J* 2012, **31**:2103–2116.

41. Carbognin E, Betto RM, Soriano ME, Smith AG, Martello G: **Stat3 promotes mitochondrial transcription and oxidative respiration during maintenance and induction of naive pluripotency**. *EMBO J* 2016, **35**:618–634.

42. Feng W, Liu HK: **Revealing the hidden powers that fuel adult neurogenesis**. *Cell Stem Cell* 2017, **20**:154–156.

43. Funfschilling U, Supplie LM, Mahad D, Boretius S, Aiman S, Edgar J, Brinkmann BG, Kassmann CM, Tzvetanova ID, Sereda W, et al.: **Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity**. *Nature* 2012, **485**:517–521.

44. Dienel GA, McKenna MC: **A dogma-breaking concept: Glutamate oxidation in astrocytes is the source of lactate during aerobic glycolysis in resting subjects**. *J Neurochem* 2014, **131**:395–398.

45. Xing F, Luan Y, Cai J, Wu S, Mai J, Gu J, Zhang H, Li K, Lin Y, Xiao X, et al.: **The Anti-Warburg effect elicited by the cAMP-PGC1α pathway drives differentiation of glioblastoma cells into astrocytes**. *Cell Rep* 2017, **18**:468–481.

46. Gascón S, Masserdotti G, Russo GL, Götz M: **Direct neuronal reprogramming: Achievements, hurdles, and new roads to success**. *Cell Stem Cell* 2017, **21**:18–34.

47. Gascón S, Murenu E, Masserdotti G, Ortega F, Russo GL, Petrik D, Deshpande A, Heinrich C, Karow M, Robertson SP, et al.: **Identification and successful negotiation**

of a metabolic checkpoint in direct neuronal reprogramming. *Cell Stem Cell* 2016, **18**:396–409.

***In this study, the authors investigated the mechanisms underlying the direct conversion of astrocytes into neurons. They observed that the metabolic switch to OXPHOS is critical for this process and identified ferropoptosis inhibitors and antioxidants as efficient promoters of direct reprogramming both *in vitro* and *in vivo*.**

48. Hayakawa K, Esposito E, Wang X, Terasaki Y, Liu Y, Xing C, Ji X, Lo EH: **Transfer of mitochondria from astrocytes to neurons after stroke**. *Nature* 2016, **533**:551–555.

****This work reported that mice astrocytes can release functional mitochondria that are uptaken by neurons. The authors showed that this extraceullar mitochondrial transfer was induced by ischemic insults and its repression worsened the neurological outcome in mice.**

49. Lin MT, Beal MF: **Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases**. *Nature* 2006, **443**:787–795.

50. Carelli V, Chan DC: **Mitochondrial DNA: Impacting central and peripheral nervous systems**. *Neuron* 2014, **84**:1126–1142.

51. Puri R: **Protecting mitochondrial health: A unifying mechanism in adult neurogenesis**. *J Neurosci* 2017, **37**:6603–6605.

52. Agnihotri SK, Shen R, Li J, Gao X, Büeler H: **Loss of PINK1 leads to metabolic deficits in adult neural stem cells and impedes differentiation of newborn neurons in the mouse hippocampus**. *FASEB J* 2017, **31**:2839–2853.

53. Voloboueva LA, Sun X, Xu L, Ouyang Y-B, Giffard RG: **Distinct effects of miR-210 reduction on neurogenesis: Increased neuronal survival of inflammation but reduced proliferation associated with mitochondrial enhancement**. *J Neurosci*

2017, **37**:3072–3084.

54. Brennand K, Savas JN, Kim Y, Tran N, Simone A, Hashimoto-Torii K, Beaumont KG, Kim HJ, Topol A, Ladran I, et al.: **Phenotypic differences in hiPSC NPCs derived from patients with schizophrenia**. *Mol Psychiatry* 2015, **20**:361–368.

***In this study, the authors showed that the gene signature of schizophrenia detected in iPSC-derived neurons was conserved also in iPSC-derived NPCs. They then used schizophrenia-NPCs to unveil disease-related phenotypes including defective cytoskeletal remodeling and oxidative stress**.

55. Tyynismaa H, Suomalainen A: **Mouse models of mitochondrial DNA defects and their relevance for human disease.** *EMBO Rep* 2009, **10**:137–143.

56. Jain IH, Zazzeron L, Goli R, Alexa K, Schatzman-Bone S, Dhillon H, Goldberger O, Peng J, Shalem O, Sanjana NE, et al.: **Hypoxia as a therapy for mitochondrial disease**. *Science (80-)* 2016, **352**:54–61.

****This work identified the hypoxia response as a suppressor of mitochondrial dysfunction. The authors demonstrated that chronic hypoxia treatment significantly improved the pathogenesis and life span in a mouse model of the mitochondrial disease Leigh syndrome.**

Figure legends

Figure 1. Mitochondrial metabolism and dynamics during neurogenesis. Cartoon depicting the orchestration of metabolic programs and mitochondrial states during the generation of neurons and glia based on the studies conducted in mouse *in vivo* and in PSC derivatives *in vitro*. The color code refers to the energy metabolism of the cells: blue for glycolysis (in PSCs, NSCs, astrocytes, oligodendrocytes, and PSC-derived NPCs grown with basal FGF), light red for intermediate OXPHOS metabolism (in proliferative IPCs and PSC-derived NPCs cultured with LIF), and dark red for marked OXPHOS metabolism (in mature neurons). The grey arrows above the cells refer to the reported proliferative rates. The morphology of mitochondria is simplified and shown as non-fused roundish organelles with sparse cristae (in PSC, glycolytic NPCs, and glial progenitors), as partly elongated organelles (in NSCs, IPCs, oxidative NPCs, and astrocytes and oligodendrocytes), and as strongly elongated organelles (in mature neurons). Abbreviations: PSC= pluripotent stem cell; NSC= neural stem cell; NPC= neural progenitor cell; IPC= intermediate progenitor cell; OXPHOS= oxidative phosphorylation.


Potency
PSC
+FGF
+LIF
NSC
NPC
NPC
Neural
Progenitor (IPC)
Glial
Progenitor
Glial
Progenitor
Neuron
Astrocyte
Oligoden
-drocyte
Neuron
Astrocyte
Oligoden
-drocyte
OXPHOS
Glycolysis
Neurogenesis in mouse *in vivo*
Neurogenesis in human *in vitro*